Alexey V. Danilov, MD, PhD, on Ibrutinib, Acalabrutinib, and Other Agents for CLL: Expert Perspective on Benefits and Risks

Posted: Wednesday, August 25, 2021

Alexey V. Danilov, MD, PhD, of City of Hope, discusses the agents approved for use as first-line treatment of chronic lymphocytic leukemia, other classes of agents that may be used in combination with a BTK inhibitor, and some clinical pearls on the drugs’ activity and side effects.